Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A2A Pharma KRAS inhibitor
- Development stage
- Preclinical
- Lead developer
- A2A Pharma
- Modality
- Small Molecules
01
Overview
A2A Pharma is developing an unnamed small-molecule inhibitor targeting the KRAS protein for the treatment of various cancers harboring KRAS mutations. KRAS is a member of the RAS family of GTPases and is one of the most frequently mutated oncogenes in human cancers, particularly in pancreatic, colorectal, and lung adenocarcinomas. Mutations in KRAS lead to constitutive activation of downstream signaling pathways, such as MAPK/ERK and PI3K/AKT, which drive uncontrolled cell proliferation and survival. This program utilizes A2A Pharma's SCULPT computational platform to design highly selective inhibitors and is currently in the preclinical stage of development.
02
Targets
Beyond the preview
Go deeper on A2A Pharma KRAS inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A2A Pharma KRAS inhibitor.